Paul Tudor Jones Bristol Myers Squibb CO Put Options Transaction History

Tudor Investment Corp Et Al

9 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	SELL	$39.66 - $51.75 $19.8 Million - $25.8 Million	-498,600 Reduced 49.71%	504,500 $26.1 Million
Q2 2024 Aug 14, 2024	BUY	$40.25 - $52.99 $27.2 Million - $35.9 Million	676,700 Added 207.32%	1,003,100 $41.7 Million
Q1 2024 May 15, 2024	SELL	$47.98 - $54.4 $14.2 Million - $16.1 Million	-296,600 Reduced 47.61%	326,400 $17.7 Million
Q4 2023 Feb 14, 2024	BUY	$48.48 - $57.85 $27 Million - $32.3 Million	557,900 Added 856.99%	623,000 $32 Million
Q3 2023 Nov 15, 2023	BUY	$57.89 - $64.73 $283,661 - $317,177	4,900 Added 8.14%	65,100 $3.78 Million
Q2 2023 Aug 14, 2023	BUY	$63.71 - $70.74 $3.84 Million - $4.26 Million	60,200 New	60,200 $3.85 Million
Q2 2022 Aug 15, 2022	SELL	$72.62 - $79.98 $1.66 Million - $1.82 Million	-22,800 Reduced 80.57%	5,500 $424,000
Q4 2021 Feb 14, 2022	BUY	$53.63 - $62.52 $1.12 Million - $1.3 Million	20,800 Added 277.33%	28,300 $1.77 Million
Q3 2021 Nov 15, 2021	BUY	$59.17 - $69.31 $443,775 - $519,825	7,500 New	7,500 $446,000

2,536

1.47B

31.6M

35M

Ticker BMY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 2,126,160,000
Market Cap $123B
Description
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...

Get notified when there are updates to the investment portfolio of Tudor Investment Corp Et Al, based on Form 13F filings with the SEC.

Stay updated on Tudor Investment Corp Et Al and Paul Tudor Jones with notifications on news.